106 related articles for article (PubMed ID: 11499653)
1. Multitarget therapy with a corticosteroid, cyclosporine and mycophenolate mofetil for idiopathic membranous nephropathy: a prospective randomized controlled trial.
Duan Y; Bai Y; Guo W; Wang L; Dai W; Guo W; Huang H; Liu W; Diao Z
Nephrol Dial Transplant; 2023 Dec; 39(1):95-102. PubMed ID: 37437905
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial.
Howman A; Chapman TL; Langdon MM; Ferguson C; Adu D; Feehally J; Gaskin GJ; Jayne DR; O'Donoghue D; Boulton-Jones M; Mathieson PW
Lancet; 2013 Mar; 381(9868):744-51. PubMed ID: 23312808
[TBL] [Abstract][Full Text] [Related]
3. Optimized rituximab regimen versus recommended regimen for idiopathic membranous nephropathy: A single-center retrospective cohort study.
Yan P; Fang X; Ke B
Int Immunopharmacol; 2024 Mar; 130():111718. PubMed ID: 38377859
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressive regimens based on Cyclophospamide or Calcineurin inhibitors: Comparison of their effect in the long term outcome of Primary Membranous Nephropathy.
Stangou M; Marinaki S; Papachristou E; Kolovou K; Sambani E; Zerbala S; Papadea P; Balafa O; Rapsomanikis KP; Andrikos A; Manolakaki P; Papadopoulou D; Mitsopoulos E; Liakou H; Andronikidi PE; Choulitoudi V; Moustakas G; Galitsiou D; Dafnis E; Stylianou K; Stefanidis I; Golfinopoulos S; Panagoutsos S; Tsilivigkou M; Papadogianakis A; Tzanakis I; Sioulis A; Vlachakos D; Grapsa E; Spaia S; Kaperonis N; Paliouras C; Dioudis C; Papoulidou F; Apostolou T; Iatrou C; Boletis I; Goumenos D; Papagianni A
PLoS One; 2019; 14(8):e0217116. PubMed ID: 31404062
[TBL] [Abstract][Full Text] [Related]
5. Primary membranous nephropathy in the Italian region of Emilia Romagna: results of a multicenter study with extended follow-up.
Albertazzi V; Fontana F; Giberti S; Aiello V; Battistoni S; Catapano F; Graziani R; Cimino S; Scichilone L; Forcellini S; De Fabritiis M; Sara S; Delsante M; Fiaccadori E; Mosconi G; Storari A; Mandreoli M; Bonucchi D; Buscaroli A; Mancini E; Rigotti A; La Manna G; Gregorini M; Donati G; Cappelli G; Scarpioni R;
J Nephrol; 2024 Mar; 37(2):471-482. PubMed ID: 37957455
[TBL] [Abstract][Full Text] [Related]
6. Hyperspectral imaging to predict the effect of cyclophosphamide in primary membranous nephropathy.
Liu W; Hou X; Li Y; Wang Z
Photodiagnosis Photodyn Ther; 2023 Dec; 44():103751. PubMed ID: 37634608
[TBL] [Abstract][Full Text] [Related]
7. Case report: Successful treatment of refractory membranous nephropathy with telitacicept.
Zhang L; Jin H; Wang D; Wang Y
Front Immunol; 2023; 14():1268929. PubMed ID: 37915584
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of Mahuang Fuzi and Shenzhuo Decoction for treatment of primary membranous nephropathy: a multicenter prospective trial.
Zhang N; Jiang H; Dai H; Huang S; Zhao Q; Zhang N; Liu W; Dong Z; Gao Y; Dong X; Hu Y; Hou F; Rui H; Liu Q; Liu B
Ren Fail; 2024 Dec; 46(1):2320834. PubMed ID: 38482580
[TBL] [Abstract][Full Text] [Related]
9. Effects of tacrolimus on proteinuria in Chinese and Indian patients with idiopathic membranous nephropathy: the results of machine learning study.
Rui M; Jiang L; Pan JJ; Huang XT; Cui JF; Zhang SJ; He SM; Han HH; Chen X; Wang DD
Int Urol Nephrol; 2024 Apr; ():. PubMed ID: 38642210
[TBL] [Abstract][Full Text] [Related]
10. Effect of cyclophosphamide combined with glucocorticoid therapy on idiopathic membranous nephropathy: A multicenter open-label randomized controlled trial.
Wang J; Bian D; Sun J
Clin Nephrol; 2024 Apr; ():. PubMed ID: 38606849
[TBL] [Abstract][Full Text] [Related]
11. Prediction of immunotherapy response in idiopathic membranous nephropathy using deep learning-pathological and clinical factors.
Wei X; Long M; Fan Z; Hou Y; Zhu X; Qu Z; Du Y
Front Endocrinol (Lausanne); 2024; 15():1328579. PubMed ID: 38524629
[TBL] [Abstract][Full Text] [Related]
12. Neutrophil-to-lymphocyte ratio is an independent risk factor for proteinuria non-remission in idiopathic membranous nephropathy.
Zhuo N; Wang G; Wu G
Int Urol Nephrol; 2024 May; 56(5):1775-1776. PubMed ID: 37919620
[No Abstract] [Full Text] [Related]
13. Urinary single-cell sequence analysis of the urinary macrophage in different outcomes of membranous nephropathy.
Liu X; Zhao Y; Niu Y; Xie Q; Nie H; Jin Y; Zhang Y; Lu Y; Zhu S; Zuo W; Yu C
Clin Kidney J; 2023 Dec; 16(12):2405-2416. PubMed ID: 38046013
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of a second course of immunosuppressive therapy in patients with membranous nephropathy and persistent or relapsing disease activity.
du Buf-Vereijken PW; Wetzels JF
Nephrol Dial Transplant; 2004 Aug; 19(8):2036-43. PubMed ID: 15187191
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD20 should be the first-line treatment in high-risk membranous nephropathy.
Zand L; Fervenza FC
Clin Kidney J; 2023 Sep; 16(9):1420-1425. PubMed ID: 37669312
[TBL] [Abstract][Full Text] [Related]
16. Intravenous cyclophosphamide and oral prednisolone is a safe and effective treatment option for idiopathic membranous nephropathy.
Mathrani V; Alejmi A; Griffin S; Roberts G
Clin Kidney J; 2017 Aug; 10(4):450-454. PubMed ID: 28852480
[TBL] [Abstract][Full Text] [Related]
17. Controversies in the treatment of idiopathic membranous nephropathy.
Waldman M; Austin HA
Nat Rev Nephrol; 2009 Aug; 5(8):469-79. PubMed ID: 19581908
[TBL] [Abstract][Full Text] [Related]
18. Short- and long-term efficacy of oral cyclophosphamide and steroids in patients with membranous nephropathy and renal insufficiency. Study Group.
Branten AJ; Wetzels JF
Clin Nephrol; 2001 Jul; 56(1):1-9. PubMed ID: 11499653
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate.
du Buf-Vereijken PW; Branten AJ; Wetzels JF;
Nephrol Dial Transplant; 2004 May; 19(5):1142-8. PubMed ID: 14993502
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
